tedizolid phosphate — Medica

Initial criteria

• For acute bacterial skin and skin structure infections caused by MRSA, selected Streptococcus species (Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group) and Enterococcus faecalis – Approve for up to 6 days of therapy
• For continuation of Sivextro therapy in the outpatient setting – Approve for up to 6 days of therapy in patients transitioning from Sivextro IV therapy to oral therapy
• If there is insufficient information available to make a determination regarding coverage and the prescriber or representative cannot be contacted – Approve for up to 6 days of therapy

Approval duration

up to 6 days